A Phase I/II Study of HE3235 in Patients With Prostate Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Dwight Stickney, MD
Harbor Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Scottsdale, Arizona, United States
- Facility name not stated
Encinitas, California, United States
- Facility name not stated
Roseville, California, United States
- Facility name not stated
San Francisco, California, United States
- Facility name not stated
New York, New York, United States
- Facility name not stated
Charlotte, North Carolina, United States
- Facility name not stated
San Antonio, Texas, United States
- Facility name not stated
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2008
- Primary completion
- 31 Mar 2011
- Completion
- 31 Mar 2011
- Last update posted
- 9 Mar 2011
- Registered enrollment
- 64
- Registry id
- NCT00716794
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.